Capmatinib (Tabrecta) is a small-molecule inhibitor targeting the MET kinase, developed by Novartis and granted accelerated approval by the U.S. FDA in 2020. As a precision therapy, it has demonstrated significant efficacy in the treatment of non-small cell lung cancer (NSCLC).

Indication of Capmatinib (Tabrecta)

Core Target Population

Capmatinib is specifically indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have been confirmed (via an FDA-approved detection method) to harbor mutations that cause MET exon 14 skipping.

Precondition for Administration

Prior to use, the status of MET exon 14 skipping mutation must be confirmed through molecular testing.

Specification and Physical Properties of Capmatinib (Tabrecta)

Dosage Specifications

150 mg Tablet:

Appearance: Light orange-brown, oval-shaped, film-coated tablet with beveled edges.

Imprint: No score line; one side is embossed with "DU" and the other side with "NVR".

200 mg Tablet:

Appearance: Yellow, with the same oval-shaped, film-coated design and beveled edges.

Imprint: No score line; marked with "LO" on one side and "NVR" on the other.

Formulation Characteristics

Both tablet strengths use a specialized coating process, and their core components include excipients such as microcrystalline cellulose and crospovidone.

The coating of the 150 mg tablet contains colorants like iron oxide red and iron oxide yellow, while the 200 mg tablet only contains iron oxide yellow.

Important Note: Tablets must be swallowed whole; do not break, crush, or chew them.

Storage Method of Capmatinib (Tabrecta)

Routine Storage Conditions

The original packaging of capmatinib should be stored at 20–25°C (68–77°F). Short-term storage within the range of 15–30°C (59–86°F) is permitted.

Moisture protection is essential: the desiccant inside the packaging must be kept in the bottle at all times.

Management After Opening

After the medicine bottle is first opened, the remaining medication must be used up within 6 weeks; any unused portion beyond this period should be discarded.

This strict requirement stems from the formulation’s sensitivity to humidity—improper storage may lead to reduced drug efficacy.